CRNX Stock Overview
A clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors.
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Crinetics Pharmaceuticals, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$46.28 |
| 52 Week High | US$53.70 |
| 52 Week Low | US$15.76 |
| Beta | 0.63 |
| 1 Month Change | -1.95% |
| 3 Month Change | 7.80% |
| 1 Year Change | 112.49% |
| 3 Year Change | 165.21% |
| 5 Year Change | 76.17% |
| Change since IPO | 88.82% |
Recent News & Updates
Most Shareholders Will Probably Agree With Crinetics Pharmaceuticals, Inc.'s (NASDAQ:CRNX) CEO Compensation
Jun 01
Crinetics: Earlier Data Release For CAH Treatment Bodes Well For Upcoming Conference Data
May 23Recent updates
Most Shareholders Will Probably Agree With Crinetics Pharmaceuticals, Inc.'s (NASDAQ:CRNX) CEO Compensation
Jun 01Crinetics: Earlier Data Release For CAH Treatment Bodes Well For Upcoming Conference Data
May 23Crinetics: Paltusotine's Phase 3 Triumph Transforms Trajectory (Rating Upgrade)
Feb 29Crinetics Pharmaceuticals (NASDAQ:CRNX) Is In A Good Position To Deliver On Growth Plans
Nov 28Is Crinetics Pharmaceuticals (NASDAQ:CRNX) In A Good Position To Invest In Growth?
Aug 08Crinetics Pharmaceuticals (NASDAQ:CRNX) Is In A Good Position To Deliver On Growth Plans
Dec 31Here's Why We're Not Too Worried About Crinetics Pharmaceuticals' (NASDAQ:CRNX) Cash Burn Situation
Sep 14Crinetics Pharmaceuticals GAAP EPS of -$0.81 misses by $0.15, revenue of $0.44M misses by $0.28M
Aug 12We're Not Very Worried About Crinetics Pharmaceuticals' (NASDAQ:CRNX) Cash Burn Rate
Jun 15Crinetics: Late-Stage Acromegaly Disease Studies Will Be Major Inflection Point
Jun 13Crinetics Pharmaceuticals: Endocrinology Focus To Pay Off As Multi-Faceted Pipeline Makes Progress
Apr 24Crinetics Pharmaceuticals (NASDAQ:CRNX) Is In A Good Position To Deliver On Growth Plans
Jan 19Crinetics Pharmaceuticals appoints Garlan Adams as general counsel
Jun 16Here's Why We're Not Too Worried About Crinetics Pharmaceuticals' (NASDAQ:CRNX) Cash Burn Situation
May 13Crinetics Pharmaceuticals EPS misses by $0.04
May 06Shareholder Returns
| CRNX | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -2.5% | -0.4% | -0.6% |
| 1Y | 112.5% | 5.4% | 22.5% |
Return vs Industry: CRNX exceeded the US Biotechs industry which returned 5.4% over the past year.
Return vs Market: CRNX exceeded the US Market which returned 22.5% over the past year.
Price Volatility
| CRNX volatility | |
|---|---|
| CRNX Average Weekly Movement | 8.1% |
| Biotechs Industry Average Movement | 10.7% |
| Market Average Movement | 5.8% |
| 10% most volatile stocks in US Market | 15.7% |
| 10% least volatile stocks in US Market | 2.9% |
Stable Share Price: CRNX has not had significant price volatility in the past 3 months.
Volatility Over Time: CRNX's weekly volatility (8%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2008 | 290 | R. Struthers | www.crinetics.com |
Crinetics Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company’s lead product candidate is paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist, which is in Phase 3 trial for the treatment of acromegaly; and Phase 2 trial for treating carcinoid syndrome associated with neuroendocrine tumors. It is also developing CRN04894, an investigational oral nonpeptide product candidate to antagonize the adrenocorticotrophic hormone (ACTH) receptor that has completed a Phase 1 study for the treatment of diseases caused by excess ACTH, including congenital adrenal hyperplasia and Cushing’s disease.
Crinetics Pharmaceuticals, Inc. Fundamentals Summary
| CRNX fundamental statistics | |
|---|---|
| Market cap | US$3.50b |
| Earnings (TTM) | -US$235.46m |
| Revenue (TTM) | US$1.97m |
1,849x
P/S Ratio-15.5x
P/E RatioIs CRNX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| CRNX income statement (TTM) | |
|---|---|
| Revenue | US$1.97m |
| Cost of Revenue | US$14.87m |
| Gross Profit | -US$12.90m |
| Other Expenses | US$222.57m |
| Earnings | -US$235.46m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -2.99 |
| Gross Margin | -653.44% |
| Net Profit Margin | -11,928.27% |
| Debt/Equity Ratio | 0% |
How did CRNX perform over the long term?
See historical performance and comparison